Morphic to Present at November Investor Conferences
Morphic Therapeutic (Nasdaq: MORF) announces participation in Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference, presenting on new oral integrin therapies for chronic diseases. Live webcasts available on company website.
11/10/2023 - 08:00 AM
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023 Time: 5:00 PM GMT/12:00 PM ET A live webcast of the presentation will be available on the Investor section of the Morphic website . An archived replay will be available on the company’s website following the conference.
Evercore ISI HealthCONx Conference Presentation Date: Thursday, November 30, 2023 Time: 9:10 AM ET A live webcast of the presentation will be available on the Investor section of the Morphic website . An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com .
Contacts Morphic Therapeutic Chris Erdmanchris.erdman@morphictx.com 617.686.1718
What is the company participating in?
Morphic Therapeutic (Nasdaq: MORF) is participating in the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
What will they be presenting?
They will be presenting on a new generation of oral integrin therapies for the treatment of serious chronic diseases.
Where can the live webcasts be accessed?
The live webcasts will be available on the Investor section of the Morphic website.
When will the presentations take place?
The Fireside Chat at the Jefferies London Healthcare Conference will be on Tuesday, November 14, 2023, at 5:00 PM GMT/12:00 PM ET. The presentation at the Evercore ISI HealthCONx Conference will be on Thursday, November 30, 2023, at 9:10 AM ET.
MORF Rankings
#3755 Ranked by Stock Gains
MORF Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Waltham
About MORF
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.